

Application No.: 09/724,953
Amdt. Submitted on May 27, 2003
Reply to Office Action of November 27, 2002

PATENT

Claim 21. (Currently Amended) The method of claim ~~20~~11, wherein said adjuvant is selected from the group consisting of QS21, monophosphoryl lipid, and alum and Freund's adjuvant.

Claim 22. (Currently Amended) The method of claim 11, wherein said ~~immunological~~ immune response is characterized by a serum titer of the antibodies of at least 1:1000 with respect to said amyloid component.

Claim 23. (Currently Amended) The method of claim 22, wherein said serum titer of the antibodies is at least 1:5000 with respect to said ~~fibril~~ amyloid component.

Claim 24. (Currently Amended) The method of claim 11, wherein said ~~immunological~~ immune response is characterized by a serum ~~amount~~ titer of immunoreactivity the antibodies corresponding to greater than about four times higher than a serum ~~level~~ titer of immunoreactivity anti- A β antibodies measured in a pre-treatment control serum sample.

Claim 25. (Currently Amended) The method of claim 24, wherein said serum ~~amount~~ titer of immunoreactivity the antibodies is measured at a serum dilution of about 1:100.

Claims 26-57: (Canceled)

Claim 58. (New) The method of claim 11, wherein the disorder is hereditary Alzheimer's disease, Down's syndrome, hereditary cerebral hemorrhage(Dutch type), sporadic cerebral amyloid angiopathy, or inclusion body myositis.